WHO Chemical Risk Assessment Workshop on new and emerging risks to human health from chemicals RIVM is hosting an international workshop on new and emerging risks from chemicals on 20 and 21 February 2019.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Kick off European Project VITAL: Vaccines and InfecTious diseases in the Ageing popuLation Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Greater influx of migrants not expected to lead to an increase in cases of tuberculosis According to the RIVM report ‘Tuberculosis in the Netherlands 2014’, a total of 823 people were diagnosed with TB last year. That is 21 fewer patients than in 2013.
Replacement possible for products with carcinogenic formaldehyde There seem to be sufficient alternatives available for the majority of disinfectants and preservatives containing the carcinogenic substance formaldehyde.
WHO’s first ever global estimates of foodborne diseases: children under five account for almost one third of deaths Almost one third (30%) of all deaths from foodborne diseases are in children under the age of five years, despite the fact that they make up only 9% of the global population.
Building blocks for a definition of microplastics The Dutch National Institute for Public Health and the Environment, RIVM has described building blocks for a definition of microplastics.
Jacco Wallinga appointed extraordinary Professor at LUMC From 1 September, Jacco Wallinga will hold the chair in Mathematical Modelling of Infectious Diseases at the department of Medical Statistics and Bio-informatics of the Leiden University Medical Ce
Little incentive from pharmaceutical legislation to promote alternatives to animal testing Current pharmaceutical legislation does not impose any legal constraints on the use of alternatives to animal testing, but neither does it actively encourage the use of these alternatives.